Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | What role will CE/BZA have for menopausal symptoms in women with breast cancer?

Swati Kulkarni, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, comments on the potential benefits of conjugated estrogen/bazedoxifene (CE/BZA) for menopausal symptoms in women concerned about breast cancer risk. Women with a history of hormone replacement therapy or at higher risk of breast cancer may consider CE/BZA as a treatment option for menopausal symptoms, although further research is needed to confirm its role in prevention. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yeah, so I think the main thing that our study showed is that it, you know, women, you know, who are maybe concerned about their risk of breast cancer because, you know, hormone replacement therapy or menopausal treatments, you know, they’ve gotten such a bad rap over the past 10, you know, 10 or 15 years. And so what, you know, our study really suggests that it’s, you know, women who are concerned about their risk of breast cancer can feel comfortable taking this medication for their menopausal symptoms...

Yeah, so I think the main thing that our study showed is that it, you know, women, you know, who are maybe concerned about their risk of breast cancer because, you know, hormone replacement therapy or menopausal treatments, you know, they’ve gotten such a bad rap over the past 10, you know, 10 or 15 years. And so what, you know, our study really suggests that it’s, you know, women who are concerned about their risk of breast cancer can feel comfortable taking this medication for their menopausal symptoms. And I would say that also maybe women who are concerned, you know, maybe they’re maybe at a little bit higher risk of developing breast cancer. They also can consider this as a potential agent for menopausal symptoms. We can’t really say too much about its role in prevention at this time. As I mentioned before, you know, this is a phase two study, you know, a relatively small number of patients. The next step really would be to conduct a larger phase three study to actually test it, you know, in the prevention setting that, you know, either for, you know, in high-risk women or in women with DCIS. So that would have to be the next step before we could consider it, you know, along the same lines of what we have for, you know, along the same data that we have for tamoxifen and aromatase inhibitors. But it’s still, you know, again, I just think it’s really exciting that a menopausal medication has this potential, you know, that potential is out there.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...